COVID Resilient Environment and Clinical Trials
Date and Time
Thursday Nov 19, 2020
12:00 PM - 1:30 PM EST
November 19
Noon to 1:30 p.m.
Location
GoToWebinar
Fees/Admission
Sign up here and you will receive the GoToWebinar link to complete your registration. If you have any registration questions, please contact our events director, Amber Niebauer.
If you are not a NCBIO member and would like to join, please contact our membership director, Laura Gunter.
Contact Information
Hosted by NCBIO, Amber Niebauer, Events Director
Send Email
Description
Our panelists will explore how COVID-19 has affected clinical trials, with an emphasis on how trials are successfully decentralizing. We’ll hear from a clinical research organization with focus on using digital health, novel trial modes, and patient networks and engagement for how a virtual trial can work practically; an attorney connected to the FDA regulation of clinical trials; a gene therapy company with an ongoing clinical trial; and a large pharma manufacturer with years of clinical experience in both vaccines and treatments.
- Phil Collis, Ph.D., vice President, global development, BioCryst Pharmaceuticals (moderator)
- Amy Cramer, director, global product development strategic partnerships, Pfizer
- Tina Papagiannopoulos, associate, Foley Hoag
- Kristen Pappas, associate director, bluebird bio
- David Tripi, vice president, innovation and customer engagement, IQVIA
